Your cutting-edge technology deserves better attention.
Biotech companies dominate the new drug pipelines and the emerging biotech is the driving force of most of the innovative therapies for untreated diseases. Limited funding, intense time pressures, little experience or resources beyond the discovery phase are often the most common challenges faced by these companies. In addition, these smaller, but disruptive innovators don’t often receive enough attention from the big CROs.
VCLS understands these unique challenges. We listen to your needs and provide tailored, flexible and integrated solutions to accelerate your product development.
Agency experience, boutique approach
We believe that each client is unique and requires a tailored approach. With a team of former employees from regulatory agency and national competent authorities and decades of experience, we solve problems before they arise. We remove barriers so that you can focus on your breakthrough.
Rare disease focused “end-to-end” solutions
Our breadth of expertise encompasses the continuum of product development and commercialization, from early planning through regulatory and post-approval. With VCLS as your strategic partner, you will have access to innovative and integrated solutions that will help you achieve your next milestone.
Deep therapeutic experience
We have a wealth of expertise in major therapeutic areas with particular strength in oncology, immunology, infectious disease, hematology and CNS from early phrase through post-approval.
“You are always there for us. Thanks to your advices and actions, especially your recommendation to revise the initial strategy which allowed us to obtain one of the accelerated programs!”
Europe-based Biotech Company